September 20, 2021
FDA committee votes against COVID-19 vaccine boosters for general population
Editor's Note
The Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee on September 17 voted that there was not enough safety and effectiveness data to approve a third Pfizer COVID-19 vaccine dose for those 16 years and older.
The committee did vote to recommend approval of a booster dose for people 65 years and older and those at high risk of severe COVID-19.
The committee also recommended approval of a booster for those with occupational risks, such as healthcare workers and teachers.
Free Daily News
- Quality Improvement: Reduce Specimen Labeling Errors
- Staffing Strategy: Grow Your Middle Management
- Olympus issues voluntary labeling update for bronchoscopes used with laser therapy equipment
- NorthStar Anesthesia scales ASC partnerships in Georgia with transparent, clinician-driven model
- Targeted intraoperative radiation slashes pancreatic cancer recurrence to 5%
- Ambient AI reshapes nursing workflows and boosts patient interaction
- Session: Developing a complex spine and total joint service line program in the ASC
- Session: The importance of having a comprehensive plan to prevent workplace violence in ASCs
- Session: Automate to elevate—Streamlining pre-, postoperative processes for better outcomes in ASCs
- Transparent oversight is key to safe surgical innovation
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement